Transcriptomics

Dataset Information

0

Semaglutide Exacerbates Stunting in Growth-Impaired Juvenile Male Mice via Reduced Energy Metabolism


ABSTRACT: Animals rely on linear growth to attain their full adult size. The regulators of this multifactorial process, including environmental and endocrine cues, are still incompletely understood. Notably, GLP-1, glucagon-like peptide 1 (GLP-1) has emerged as a potential player in this process. Here, we employ semaglutide, a pharmaceutical GLP-1R agonist as a tool to mechanistically dissect the interplay between GLP-1 receptor activation, energy metabolism, and linear growth during the juvenile period, independent of its clinical applications. Using a juvenile mouse model, we show that chronic semaglutide treatment lowers blood glucose without affecting food intake or weight gain in juveniles with a normal growth pattern. However, in growth-stunted juveniles, semaglutide treatment exacerbates linear growth impairment through at least 2 concomitant mechanisms: a moderate reduction in food intake, and a decreased catabolic activity incompatible with tissue growth. These data suggest a complex interplay between GLP-1 signaling, energy metabolism, and growth during juvenile development. Overall, these findings highlight the value of semaglutide as a mechanistic tool for understanding how GLP-1 receptor activation modulates growth and metabolism in juveniles, emphasizing the importance of developmental context for interpreting its effects.

ORGANISM(S): Mus musculus

PROVIDER: GSE266477 | GEO | 2024/05/07

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2022-12-09 | GSE211105 | GEO
2020-03-26 | E-MTAB-8078 | biostudies-arrayexpress
2025-03-12 | GSE288514 | GEO
2025-04-23 | GSE295272 | GEO
| PRJNA1107259 | ENA
2014-12-25 | GSE54362 | GEO
2025-04-29 | GSE293291 | GEO
2014-10-31 | GSE57188 | GEO
2014-10-31 | GSE57189 | GEO
2023-03-02 | PXD037495 | Pride